Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Malignant Lymphoma

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 61 articles:
HTML format



Single Articles


    May 2020
  1. LI C, Huang B
    CAR-Transduced Natural Killer Cells.
    N Engl J Med. 2020;382:1865-1866.
    PubMed    


  2. QUINTAS-CARDAMA A
    CAR-Transduced Natural Killer Cells.
    N Engl J Med. 2020;382:1866.
    PubMed    


    April 2020
  3. WANG M, Munoz J, Goy A, Locke FL, et al
    KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    N Engl J Med. 2020;382:1331-1342.
    PubMed     Abstract available


  4. IRIARTE C, Vaitkevicius H, Marty FM, Miller AL, et al
    Missing the Target.
    N Engl J Med. 2020;382:1353-1359.
    PubMed    


  5. MAREDIA H, Rozati S
    Advanced Mycosis Fungoides.
    N Engl J Med. 2020;382:e27.
    PubMed    


    March 2020
  6. IRIARTE C, Zambrotta M, Vaitkevicius H, Vaidya A, et al
    Missing the Target.
    N Engl J Med. 2020;382:e23.
    PubMed    


    February 2020
  7. CHI KY, Shen HN
    Extranodal Natural Killer T-Cell Lymphoma.
    N Engl J Med. 2020;382:562.
    PubMed    


  8. LIU E, Marin D, Banerjee P, Macapinlac HA, et al
    Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
    N Engl J Med. 2020;382:545-553.
    PubMed     Abstract available


    November 2019
  9. MAUS MV, Leick MB, Cornejo KM, Nardi V, et al
    Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash.
    N Engl J Med. 2019;381:1951-1960.
    PubMed    


    August 2019
  10. RASHIDI A, Courville E
    Massive Splenomegaly.
    N Engl J Med. 2019;381:e11.
    PubMed    


    April 2019
  11. SCHUSTER SJ
    Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.
    N Engl J Med. 2019;380:1586.
    PubMed    


  12. SCHWARTZ JD
    Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2019;380:1585-1586.
    PubMed    


  13. GEOFFRION D, Whittaker H
    Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2019;380:1585.
    PubMed    


    January 2019
  14. LI Y
    CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:497.
    PubMed    


  15. VALERIUS T, Rosner T, Leusen JHW
    CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:496-7.
    PubMed    



  16. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:496-498.
    PubMed    


    December 2018
  17. SCHUSTER SJ, Bishop MR, Tam CS, Waller EK, et al
    Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980.
    PubMed     Abstract available


    November 2018
  18. ADVANI R, Flinn I, Popplewell L, Forero A, et al
    CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2018;379:1711-1721.
    PubMed     Abstract available


    October 2018
  19. ALZAHRANI MF, AlJasser MI
    Nail Changes during Chemotherapy.
    N Engl J Med. 2018;379:1561.
    PubMed    


  20. BACH PB
    National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.
    N Engl J Med. 2018;379:1396-1398.
    PubMed    


    September 2018
  21. MORSCHHAUSER F, Fowler NH, Feugier P, Bouabdallah R, et al
    Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
    N Engl J Med. 2018;379:934-947.
    PubMed     Abstract available


  22. HANDY MARSHALL C, Nahas-Vigon J, Manesh R, Gelber AC, et al
    Just Beneath the Surface.
    N Engl J Med. 2018;379:968-973.
    PubMed    


  23. TIACCI E, Venanzi A, Ascani S, Marra A, et al
    High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML.
    N Engl J Med. 2018;379:981-984.
    PubMed    


    August 2018
  24. KATAOKA K, Ogawa S
    PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:696.
    PubMed    


  25. ISHITSUKA K, Utsunomiya A, Ishida T
    PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:695.
    PubMed    



  26. PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma.
    N Engl J Med. 2018;379:695-697.
    PubMed    


  27. SHAH NN, Singavi AK, Harrington A
    Daratumumab in Primary Effusion Lymphoma.
    N Engl J Med. 2018;379:689-690.
    PubMed    



  28. Genetics of Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018;379:493-494.
    PubMed    


  29. NARESH KN
    Genetics of Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018;379:493.
    PubMed    


  30. CUMMIN TE, Du MQ, Johnson P
    Genetics of Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018;379:493.
    PubMed    


    May 2018
  31. RATNER L, Waldmann TA, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.
    N Engl J Med. 2018;378:1947-1948.
    PubMed    


    April 2018
  32. BORCHARD NA, Nayak JV
    Orbital Apex Syndrome.
    N Engl J Med. 2018;378:e23.
    PubMed    


  33. CANELLOS GP, LaCasce AS
    Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:1560.
    PubMed    


  34. CRUMP M
    Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:1559-60.
    PubMed    


  35. GREER JP
    Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:1559.
    PubMed    


  36. HILAL T
    Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:1558-9.
    PubMed    



  37. Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:1558-1561.
    PubMed    


  38. SCHMITZ R, Wright GW, Huang DW, Johnson CA, et al
    Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018;378:1396-1407.
    PubMed     Abstract available


    March 2018
  39. TAM CS, Anderson MA, Pott C, Agarwal R, et al
    Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2018;378:1211-1223.
    PubMed     Abstract available


  40. ARD KL, Kelly HR, Gandhi RT, Louissaint A Jr., et al
    Case 9-2018: A 55-Year-Old Man with HIV Infection and a Mass on the Right Side of the Face.
    N Engl J Med. 2018;378:1143-1152.
    PubMed    


  41. QUINTAS-CARDAMA A
    CAR T-Cell Therapy in Large B-Cell Lymphoma.
    N Engl J Med. 2018;378:1065.
    PubMed    



  42. CAR T-Cell Therapy in Large B-Cell Lymphoma.
    N Engl J Med. 2018;378:1065.
    PubMed    


  43. YARCHOAN R, Uldrick TS
    HIV-Associated Cancers and Related Diseases.
    N Engl J Med. 2018;378:1029-1041.
    PubMed    



  44. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2018;378:878.
    PubMed    


    December 2017
  45. NAIR R, Tabchi S, Hagemeister F
    Obinutuzumab Treatment of Follicular Lymphoma.
    N Engl J Med. 2017;377:2605.
    PubMed    



  46. Obinutuzumab Treatment of Follicular Lymphoma.
    N Engl J Med. 2017;377:2605-2606.
    PubMed    


  47. SCHUSTER SJ, Svoboda J, Chong EA, Nasta SD, et al
    Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    N Engl J Med. 2017;377:2545-2554.
    PubMed     Abstract available


  48. NEELAPU SS, Locke FL, Bartlett NL, Lekakis LJ, et al
    Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
    N Engl J Med. 2017 Dec 10. doi: 10.1056/NEJMoa1707447.
    PubMed     Abstract available


  49. LONGO DL, DeVita VT Jr
    Progress in the Treatment of Hodgkin's Lymphoma.
    N Engl J Med. 2017 Dec 10. doi: 10.1056/NEJMe1715141.
    PubMed    


  50. CONNORS JM, Jurczak W, Straus DJ, Ansell SM, et al
    Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2017 Dec 10. doi: 10.1056/NEJMoa1708984.
    PubMed     Abstract available


    November 2017

  51. More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.
    N Engl J Med. 2017;377:2101-2102.
    PubMed    


  52. TIBERGHIEN P, Deconinck E, Adotevi O
    More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.
    N Engl J Med. 2017;377:2101-2.
    PubMed    


    October 2017
  53. MARCUS R, Davies A, Ando K, Klapper W, et al
    Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    N Engl J Med. 2017;377:1331-1344.
    PubMed     Abstract available


  54. ARMITAGE JO, Longo DL
    Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
    N Engl J Med. 2017;377:1389-1390.
    PubMed    


    September 2017
  55. LE GOUILL S, Thieblemont C, Oberic L, Moreau A, et al
    Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
    N Engl J Med. 2017;377:1250-1260.
    PubMed     Abstract available


  56. RUSH RP, Saltman AP, Prica AA, Breiner A, et al
    Connecting the Dots.
    N Engl J Med. 2017;377:978-984.
    PubMed    


    August 2017
  57. ABRAMSON JS, McGree B, Noyes S, Plummer S, et al
    Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.
    N Engl J Med. 2017;377:783-784.
    PubMed    


  58. LACASCE AS, Flores EJ, Goldstein RH, Sohani AR, et al
    Case 25-2017.
    N Engl J Med. 2017;377:677-688.
    PubMed    


    July 2017
  59. MELANI C, Major A, Schowinsky J, Roschewski M, et al
    PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
    N Engl J Med. 2017;377:89-91.
    PubMed    


    June 2017
  60. DAVID WS, Bowley MP, Mehan WA Jr, Shin JH, et al
    Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness.
    N Engl J Med. 2017;376:2471-2481.
    PubMed    


    April 2017
  61. HOCHBERG EP, Bierer MF, Winkfield KM, Chen YB, et al
    Case 11-2017 - A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis.
    N Engl J Med. 2017;376:1461-1471.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: